Swiss regulator approves Roche-Regeneron Covid-19 drug
The Swiss medicines agency, Swissmedic, has given the green light to the monoclonal antibody cocktail Ronapreve developed by Roche and Regeneron for use in the treatment and prevention of Covid-19.
Ronapreve, a combination of two monoclonal antibodies (casirivimab and imdevimab), is approved for patients 12 years and up when “oxygen therapy or hospitalisation is not required and there is a high risk of developing a severe form of Covid-19,” Swissmedic said in a statementExternal link.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses.
The treatment can also be taken prophylactically when the immune response to Covid-19 vaccination is not adequate. It is the first drug authorised by the Swiss regulator for the prevention of Covid-19 in cases where there is not a sufficient immune response after vaccination due to other diseases or treatments.
Ronapreve is given as a single infusion into a vein or by injection under the skin. The application for the authorisation of the drug, submitted on March 5, didn’t include data on the efficacy of the drug against the Omicron variant.
Since-April, Ronapreve could be administered under the exceptions allowed in the Covid-19 Ordinance 3; an ordinance published by the Federal Council in June 2020 to combat the pandemic. This includes a list of products that can be placed on the market before the authorisation procedure is concluded.
The antibody cocktail has been authorised in several other locations including in Japan and the European Union. It has a conditional approval in the UK and Australia and is available for emergency use in the United States.
More orders
The Federal Office of Public Health (FOPH) has been building up its Covid-19 treatment reserves. On Monday, the FOPH announced that it had signed two additional contracts for more doses of both Ronapreve (4,000 doses) and the monoclonal drug sotrovimab (2,000 doses) developed by GlaxoSmithKline and Vir Biotechnology. The antibody for the latter was discovered by Swiss company Humabs BioMed.
This is on top of the 3,000 doses of each drug the government ordered earlier this year. Contract amounts are confidential for both drugs, according to the FOPH.
Popular Stories
More
Culture
Documentary portrays Swiss teenagers forced to return to parents’ homeland
French cross-border workers in Switzerland fear “discriminatory” unemployment reform
This content was published on
In the French region around Geneva, cross-border workers are protesting proposals to cut unemployment benefits for those working in Switzerland.
Swan infected with bird flu in central Switzerland
This content was published on
Switzerland has reported its first bird flu case of the season. A swan found dead in central Switzerland tested positive for the H5N1 virus.
Swiss researchers identify gene variants linked to cancer progression
This content was published on
ETH Zurich researchers explored genetic mutations’ effects on cell function and their role in cancer development and treatment using CRISPR/Cas techniques.
Explosion at Swiss company Givaudan’s US plant leaves two dead
This content was published on
Swiss flavour and fragrance maker Givaudan reported that an explosion at its Kentucky plant resulted in two deaths and several injuries.
Swisscom’s Vodafone Italia takeover cleared by Italian telecoms authority
This content was published on
Swisscom is one step closer to its planned acquisition of Vodafone Italia, as the Italian communications regulator has approved the €8 billion deal.
Swiss parliamentary committee proposes foreign aid cuts and military funding boost
This content was published on
A committee of the Swiss House of Representatives has proposed increasing funds for the military and agriculture while reducing foreign aid and asylum.
Swiss Rolex Submariner watches reach nearly $50 billion in total market value
This content was published on
The total market value of all Rolex Submariner watches ever made is nearly $50 billion, based on newly released production data.
Swiss Jew wrongfully detained due to prosecutor’s ‘bias’
This content was published on
A Jewish Swiss man was detained after the prosecutor argued he might flee to Israel. The Federal Court said this implies bias due to his Jewish faith.
US reportedly scrutinises Russian accounts UBS took over from Credit Suisse
This content was published on
The US is investigating Russian clients acquired by UBS during its takeover of Credit Suisse, according to three sources familiar with the matter.
WTO plans to reappoint Okonjo-Iweala before Trump swears in
This content was published on
Some member states of the World Trade Organization may seek to reappoint Director-General Ngozi Okonjo-Iweala, according to a document released on Tuesday.
Swiss pharma reckons with its past, present and future
This content was published on
This is the story of how making drugs helped turn a small, mountainous country into an industry titan, and what the pandemic means for its future.
This content was published on
Swiss biopharma firm Roche has been granted emergency authorisation by US authorities to sell its at-home rapid Covid-19 test starting in January.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.